Zedira’s general approach in medicine targets dysregulated transglutaminase activity in disease states.

In the human body, eight transglutaminases fulfill a broad variety of physiological functions. On the other hand, transglutaminases are involved in the pathophysiology of various disorders. Celiac disease, thrombosis, fibrosis or even cancer and such neurodegenerative diseases as Alzheimer’s, Huntington’s and Parkinson’s disease are just some examples.

Celiac Disease
Zedira’s drug candidate ZED1227 targeting dysregulated TG2 in celiac disease is currently tested in phase I clinical trials (first-in-class).
  Partnering in Drug Development
Zedira offers its proprietary drug discovery platform for partnering in drug development.
  read more     read more

Gluten Sensitive Neurological Disorders

Auto-antibodies specific for neuronal transglutaminase (TG6) can be measured with our proprietary ELISA-kits.

New: Analytical service for measurement of TG6-autoantibodies in human serum samples.
Thrombosis / Anticoagulation
Proof-of-principle for safe anticoagulation, meaning anticoagulation without increased bleeding risk using blood coagulation factor FXIIIa-blockers has recently been shown.
read more       read more


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation